Analysts Expect Ranbaxy Failure To Benefit From Indian Acquisitions

Industry analysts say the plan by Ranbaxy Laboratories to buy into other Indian drug makers and suppliers has not yet reaped benefits. Ranbaxy had acquired equity shares in four companies over the past two years to build up its drug pipeline, relying on the addition of the firms' niche products. That effort has failed to produce many results, in part because of the global financial meltdown, analysts said. They believe Daiichi Sankyo, which bought Ranbaxy, has not helped in its dispute with Zenotech Laboratories over the cost of acquiring an additional 20 percent stake. (Click here for more